ADOCIA |
Market Closed -
Other stock markets
|
After market 01:01:19 pm | |||
| 8.75 EUR | +1.51% |
|
8.605 | -1.66% |
| Mar. 22 | Adocia: announces fund-raising | CF |
| Mar. 21 | Adocia SA announced that it expects to receive ?2 million in funding | CI |
| Sales 2023 * | 18.7M 19.98M | Sales 2024 * | 50M 53.42M | Capitalization | 123M 132M |
|---|---|---|---|---|---|
| Net income 2023 * | 14M 14.96M | Net income 2024 * | 26M 27.78M | EV / Sales 2023 * | 6.76 x |
| Net Debt 2023 * | 3.3M 3.53M | Net cash position 2024 * | 22.5M 24.04M | EV / Sales 2024 * | 2.01 x |
| P/E ratio 2023 * |
4.2
x | P/E ratio 2024 * |
2.32
x | Employees | 97 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.08% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.51% | ||
| 1 week | +2.94% | ||
| Current month | -0.11% | ||
| 1 month | -0.79% | ||
| 3 months | -17.30% | ||
| 6 months | +17.45% | ||
| Current year | -24.18% |
1 week
8.20
8.89
1 month
8.2010.70
Current year
8.2012.40
1 year
2.7616.16
3 years
2.7516.16
5 years
2.7522.60
10 years
2.7594.24
| Managers | Title | Age | Since |
|---|---|---|---|
Olivier Soula
FOU | Founder | 53 | 05-12-15 |
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director of Finance/CFO | - | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director/Board Member | 67 | 21-05-20 | |
| Director/Board Member | 58 | 13-06-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 8.75 | +1.51% | 28 360 |
| 24-04-23 | 8.62 | -0.69% | 36,840 |
| 24-04-22 | 8.68 | +2.72% | 61,404 |
| 24-04-19 | 8.45 | +0.48% | 55,041 |
| 24-04-18 | 8.41 | -1.06% | 59,515 |
Real-time Euronext Paris, April 24, 2024 at 11:35 am EDT
More quotes
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.
At the end of 2022, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Calendar
2024-04-23
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.62
EUR
Average target price
9.7
EUR
Spread / Average Target
+12.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.18% | 132M | |
| -1.53% | 105B | |
| +3.44% | 97.5B | |
| +1.86% | 22.19B | |
| -16.38% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.78% | 14.52B | |
| +5.73% | 14.09B | |
| +21.92% | 10.99B |
- Stock Market
- Equities
- ADOC Stock
